



EXPANDING **PATIENT ACCESS**
TO **INNOVATIVE TREATMENTS**

BLANVER
PHARMACEUTICAL UNIT



Dear Partners,

Over the past 34 years, our company has continuously sought innovative products, economies of scale and high quality, initially in raw materials and more recently in medicines and APIs.

In recent years we have focused our efforts on the HIV areas, particularly Hepatitis C and Oncology.

With a team of doctors and specialists in each area of operation, we have developed a portfolio of medicines essential for treatment of each of these pathologies.

In order to speed up and minimize the critical stages of development, ensuring quality and supply, we acquired an API unit early in 2016.

Our experience supplying medicines for treating HIV in Brazil makes us confident of our ability to expand our operations into other countries.

We are also looking for partners with innovative products in the area of oncology for the Latin American market.

We at Blanver live our mission intensively, that is to develop, produce and incorporate quality, competitive and innovative products in our portfolio, always striving to promote patient health, quality of life and well-being.

Sérgio Frangioni, Blanver Group



1984

BLANVER is founded with an Excipients Unit



1996-2000

Foundation of the Pharmaceutical Contract Manufacturing Unit
Offices opened in Europe and the USA



2005

Production of antiretroviral drugs (through outsourcing)

COMPANY PROFILE

Blanver is a Brazilian multinational company that develops and manufactures medicines and APIs.

In our pharmaceutical unit, we currently manufacture HIV & Hepatitis solid oral forms for patients in Brazil through partnerships with the Ministry of Health and official laboratories

Blanver develops, produces and incorporates quality and competitive innovative products in its portfolio, always striving to promote people's health, quality of life and well-being.

We currently have two manufacturing plants in São Paulo, Brazil.



**Brazilian
Pharmaceutical
Company**




**High R&D
Investment**



Compliance Driven



**Modern Infrastructure
& Labs**



**Cutting-edge
Technology**



2009-2011

1st PDP* in Brazil: tenofovir
New pharmaceutical plant



2013-2014

1st dose combination:
tenofovir + lamivudine
for HIV in the PDP model



2015-2017

Contract manufacturing and
excipients divestment
Focus on the development and
production of own medicines
API Unit acquisition
Internationalization
plan for our Pharmaceutical Unit
Oncology Business Unit

*PDP: Productive Development Partnership, for the development, transfer and absorption of technology and production from private to public laboratories. Established by the Brazilian government in 2009 with a focus on distribution of strategic medicines to the Brazilian population. This policy stimulates local production of high-cost drugs and guarantees these producers a long-term contracts with the government.

GROWTH STRATEGY



HIV AND HEPATITIS CARE

PDP - Productive Development Partnerships

1st Pharma company in Brazil to have a PDP approved by the Brazilian government for supply of strategic products. We are committed to promoting health and well-being and are working continuously to increase patient access to innovative treatments.

Verticalization

We manufacture APIs for our medicines. Our own production of strategic APIs is fundamental to gain/By producing strategic APIs, we gain better knowledge of our final products, since we have vertical control of the critical production stages.

Internationalization

With the objective of expanding our presence in Brazil and internationally, our strategy is to increase our operations in the international market through partnerships to export our medicines in the HIV and Hepatitis segments.

In HIV and Hepatitis, our focus is on building a portfolio with the main treatment lines recommended by the World Health Organization and the

Brazilian Ministry of Health, thus meeting the needs of both the local market and our internationalization plan.

We are certified by ANVISA and are in the process of receiving certification from the main international regulatory agencies, such as the WHO, EMA, FDA, and Health Canada, in order to support our internationalization strategy.



INTERNATIONAL GMP CERTIFICATION PLAN

- EMA
- WHO
- Health Canada
- FDA

ONCOLOGY:

A NEW FRONTIER FOR BLANVER

With a dedicated oncology unit, our focus is on providing access to the main cancer treatments: prostate, breast, lung, among others.

We are looking for strategic alliances with partners of recognized international quality who share our values in order to promote patient health and well-being.

We are open to in-licensing opportunities for Brazil and other Latin America countries.

Become one of our partners!



STRONGLY COMPLIANCE-DRIVEN



LEGAL COMPLIANCE

- Code of Conduct
- Code of Ethics
- Ombudsman Channel



INFORMATION SECURITY

- Integrated ERP-Datasul
- General IT Controls
- Information Security Policy
- Infrastructure Monitoring
- Document Encryption Tool



ENVIRONMENT CONTROL



MANAGEMENT SYSTEMS

- Critical processes mapped and monitored



MONITORING RISKS & COMPLIANCE

- Risk Management
- Fraud Prevention
- Contract Management (Espaider)
- Annual Audits (External and Internal)

R&D AND CATALOG



R&D STRUCTURE

Blanver understands that innovation is essential for business success and growth, therefore it invests constantly in research and development to offer innovative products.

With a modern infrastructure, labs and cutting-edge technology, our R&D sector is ready to meet the most varied and challenging demands.

We have a highly qualified team, composed of engineers, chemists and pharmacists, many with PhD and Masters degrees.

CATALOG PRODUCTS

Our catalog offers HIV and Hepatitis products. We also have a dedicated R&D committee for HIV.



WORKING FOR OVER **30 YEARS** WITH **PASSION** AND A **COMMITMENT TO QUALITY**

HIV & HEPATITIS

ONCOLOGY & HEMATOLOGY





MORUMBI OFFICE

Rua Francisco Tramontano, 101
5º andar – salas 507 a 512
São Paulo – São Paulo – Brazil
05686-010
+55 (11) 3199-8700
contatobr@blanver.com.br



PHARMACEUTICAL UNIT

Rua Joaquim Faustino
de Camargo, 201
Taboão da Serra, SP - Brasil
06767-385
+55 (11) 4138-8200



API UNIT

R. Hermínio de Mello, 311
Indaiatuba, SP - Brasil
13347-330
+55 (19) 3936-5040



BUSINESS DEVELOPMENT

bd@blanver.com.br
+55 (11) 4862-0077



 blanver.com.br

 /Blanver

 /Blanver-farmoquimica